Eledon Pharmaceuticals ELDN
NASDAQ ELDN
$2.67 -0.09 (-3.26%)
At close: Nov 11, 2026 · 4:00 PM EST

Eledon Pharmaceuticals (ELDN) Gains from Sales and Divestitures (2017)

Updated

Eledon Pharmaceuticals (ELDN) reported Gains from Sales and Divestitures of -$18,000 for Q4 2017.

Analysis

Eledon Pharmaceuticals (ELDN) Gains from Sales and Divestitures (2017) Analysis & Trends

For FY2017, Eledon Pharmaceuticals posted Gains from Sales and Divestitures of -$49,000.

  • By year, Gains from Sales and Divestitures came in at -$9,000 in FY2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Eledon Pharmaceuticals 313.62 Mn 224.82 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 -18,000.00
API Access

Eledon Pharmaceuticals Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ELDN&period=max&api_key=YOUR_API_KEY